Free tool
FAERS Monitor: Aranesp
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 103951 or its brand name (Aranesp, Darbepoetin Alfa). Reports on generic versions are filed under their own applications.
Reports
54,075
Serious
48,342
89% of reports
Hospitalization
24,168
Death reported
20,052
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death16,296
- hospitalisation6,211
- off label use2,624
- anaemia2,197
- haemoglobin decreased1,664
- product storage error1,623
- pneumonia1,504
- fatigue1,491
- dyspnoea1,458
- diarrhoea1,339
- nausea1,309
- fall1,218
- asthenia1,157
- vomiting1,144
- circumstance or information capable of leading to medication error1,052
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 499 |
| 2005 | 637 |
| 2006 | 935 |
| 2007 | 935 |
| 2008 | 860 |
| 2009 | 914 |
| 2010 | 935 |
| 2011 | 1,073 |
| 2012 | 1,680 |
| 2013 | 1,536 |
| 2014 | 5,752 |
| 2015 | 6,451 |
| 2016 | 6,847 |
| 2017 | 7,062 |
| 2018 | 4,413 |
| 2019 | 1,520 |
| 2020 | 1,681 |
| 2021 | 1,595 |
| 2022 | 1,610 |
| 2023 | 2,363 |
| 2024 | 1,996 |
| 2025 | 1,434 |
| 2026 | 1,347 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,000,084 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hospitalisationSignal | 6,211 | 16.3 | 16.0 | 86,465 |
| circumstance or information capable of leading to medication errorSignal | 1,052 | 12.5 | 11.7 | 10,761 |
| deathSignal | 16,296 | 7.5 | 7.4 | 93,575 |
| product storage errorSignal | 1,623 | 7.3 | 7.0 | 8,735 |
| haemoglobin decreasedSignal | 1,664 | 6.4 | 6.1 | 7,475 |
| anaemiaSignal | 2,197 | 4.5 | 4.3 | 6,006 |
| pneumonia | 1,504 | 1.8 | 1.7 | 551 |
| fall | 1,218 | 1.4 | 1.3 | 156 |
| asthenia | 1,157 | 1.2 | 1.1 | 38 |
| off label use | 2,624 | 1.2 | 1.1 | 64 |
| dyspnoea | 1,458 | 1.0 | 1.0 | 0 |
| vomiting | 1,144 | 0.9 | 0.9 | 4 |
| diarrhoea | 1,339 | 0.8 | 0.8 | 64 |
| fatigue | 1,491 | 0.7 | 0.7 | 135 |
| nausea | 1,309 | 0.6 | 0.6 | 269 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.